Formycon AG is headquartered in Munich and is listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and has been part of the selection index SDAX since ...

MiscellaneousFormycon included in TecDAX Index of Deutsche Börse 09.01.2025 / 15:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release // January 9, ...

Approved by Health Canada for Both Subcutaneous and Intravenous Formulations to Treat Serious Inflammatory Diseases Health Canada Joins the FDA and the European Commission in Granting Regulatory ...

Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® approved by Health Canada for both subcutaneous and intravenous ...

OtulfiTM received a Health Canada Notice of Compliance (NOC) approval on December 30th for both subcutaneous and intravenous formulationsWith this approval, Fresenius Kabi Canada's immunology ...

Regulatory ApprovalFormycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 08.01.2025 / 14:30 CET/CESTThe issuer is solely ...

Pembrolizumab biosimilar is under clinical development by Formycon and currently in Phase III for Non-Small Cell Lung Cancer.

FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...